AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate

Journal of Urology

Volumn 197, Issue 1, 2017, Pages 135-142

  Todenhöfer, Tilman ^a,d   Azad, Arun ^b,e   Stewart, Craig ^a   Gao, Jian ^a   Eigl, Bernhard J ^b   Gleave, Martin E ^a   Joshua, Anthony M ^c   Black, Peter C ^a   Chi, Kim N ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e MONASH UNIVERSITY   (Australia)

Author keywords

abiraterone; androgen; biomarkers; castration resistant; neoplasm metastasis; prostatic neoplasms; receptors; tumor

Indexed keywords

ABIRATERONE ACETATE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LACTATE DEHYDROGENASE; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ABIRATERONE; ANDROSTANE DERIVATIVE; AR PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; ENRICHMENT CULTURE; GENE EXPRESSION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TREATMENT RESPONSE; VALIDATION STUDY; AGE; ANALYSIS OF VARIANCE; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANDROSTENES; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RNA, MESSENGER; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85003583757     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2016.06.094     Document Type: Article

References (30)

1. 1 Beer, T.M., Armstrong, A.J., Rathkopf, D.E., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med, 371, 2014, 424.
2. 2 Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med, 367, 2012, 1187.
3. 3 Fizazi, K., Scher, H.I., Miller, K., et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol, 15, 2014, 1147.
4. 4 Loriot, Y., Miller, K., Sternberg, C.N., et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol, 16, 2015, 509.
5. 5 Ryan, C.J., Smith, M.R., Fizazi, K., et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol, 16, 2015, 152.
6. 6 Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med, 368, 2013, 138.
7. 7 Omlin, A., Pezaro, C., Mukherji, D., et al. Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol, 64, 2013, 300.
8. 8 Chi, K.N., Kheoh, T., Ryan, C.J., et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol, 27, 2016, 962.
9. 9 Leibowitz-Amit, R., Templeton, A.J., Omlin, A., et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol, 25, 2014, 657.
10. 10 Scher, H.I., Heller, G., Molina, A., et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol, 33, 2015, 1348.
11. 11 Azad, A.A., Volik, S.V., Wyatt, A.W., et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res, 21, 2015, 2315.
12. 12 Lallous, N., Volik, S.V., Awrey, S., et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol, 17, 2016, 10.
13. 13 Romanel, A., Gasi Tandefelt, D., Conteduca, V., et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med, 7, 2015 312re10.
14. 14 Schweizer, M.T., Antonarakis, E.S., Liquid biopsy: clues on prostate cancer drug resistance. Sci Transl Med, 7, 2015 312fs45.
15. 15 Thadani-Mulero, M., Portella, L., Sun, S., et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res, 74, 2014, 2270.
16. 16 Nakazawa, M., Antonarakis, E.S., Luo, J., Androgen receptor splice variants in the era of enzalutamide and abiraterone. Horm Cancer, 5, 2014, 265.
17. 17 Antonarakis, E.S., Armstrong, A.J., Dehm, S.M., et al. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis, 19, 2016, 231.
18. 18 Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med, 371, 2014, 1028.
19. 19 Danila, D.C., Anand, A., Sung, C.C., et al. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol, 60, 2011, 897.
20. 20 Crespo, M., van Dalum, G., Ferraldeschi, R., et al. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer, 112, 2015, 1166.
21. 21 Duale, N., Brunborg, G., Ronningen, K.S., et al. Human blood RNA stabilization in samples collected and transported for a large biobank. BMC Res Notes, 5, 2012, 510.
22. 22 Olmos, D., Brewer, D., Clark, J., et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol, 13, 2012, 1114.
23. 23 Danila, D.C., Anand, A., Schultz, N., et al. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol, 65, 2014, 1191.
24. 24 Attard, G., de Bono, J.S., Logothetis, C.J., et al. Improvements in radiographic progression-free survival stratified by ERG gene status in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate. Clin Cancer Res, 21, 2015, 1621.
25. 25 Shiota, M., Bishop, J.L., Nip, K.M., et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res, 73, 2013, 3109.
26. 26 Azad, A.A., Leibowitz-Amit, R., Eigl, B.J., et al. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate, 74, 2014, 1544.
27. 27 Onstenk, W., Sieuwerts, A.M., Kraan, J., et al. Efficacy of cabazitaxel in castration-resistant prostate cancer is independent of the presence of AR-V7 in circulating tumor cells. Eur Urol, 68, 2015, 939.
28. 28 Antonarakis, E.S., Lu, C., Luber, B., et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol, 1, 2015, 582.
29. 29 Austin, D.C., Strand, D.W., Love, H.L., et al. NF-kappaB and androgen receptor variant expression correlate with human BPH progression. Prostate, 76, 2016, 491.
30. 30 Takeuchi, T., Okuno, Y., Hattori-Kato, M., et al. Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol, 8, 2016, 21.